tldrdailynews.com logo
Tag

China Biotech

All articles tagged with #china biotech

Roche Joins ALK7 Obesity Race with $1.16B Deal for Chinese Biotech Rona
biotech6 days ago

Roche Joins ALK7 Obesity Race with $1.16B Deal for Chinese Biotech Rona

Roche has entered the emerging ALK7 obesity drug market by licensing a candidate from Chinese biotech Rona Therapeutics for up to $1.16 billion. The deal includes $100 million in upfront and near-term payments, plus tiered royalties, as Roche intensifies its strategy to become a top-three obesity player. This move follows a wave of similar deals by Alnylam, Arrowhead, GSK, and Novo, all targeting ALK7 to improve weight loss durability and preserve lean mass.

via Fierce Biotech|
#alk7#biotech#china-biotech
Novartis Secures Chinese mRNA Therapy in $7.8B Deal Amid Pipeline Pressures
biopharmaceuticals17 days ago

Novartis Secures Chinese mRNA Therapy in $7.8B Deal Amid Pipeline Pressures

Novartis has agreed to pay up to $7.8 billion for exclusive worldwide rights to ABO2203, an early-stage mRNA-based T-cell engager developed by Chinese biotech Abogen Biosciences. The agreement includes a $575 million upfront payment and up to $7.2 billion in milestone payments. The therapy targets autoimmune diseases by depleting B cells using an in vivo approach that avoids traditional manufacturing complexities. This deal follows recent setbacks in Novartis’s own CAR-T programs and reflects a broader trend of Western pharmaceutical companies partnering with Chinese developers to secure future pipeline growth.

via Endpoints News|
#abogen-biosciences#autoimmune-disease#biopharmaceuticals
Death in China's brain-targeted gene-editing trial ignites ethics debate amid biotech surge
technology2 months ago

Death in China's brain-targeted gene-editing trial ignites ethics debate amid biotech surge

A young girl died in an experimental brain-targeted gene-editing trial at Shanghai Jiaotong University, prompting an ethics investigation and highlighting gaps in oversight amid China's booming biotech sector; authorities have since tightened rules around investigator-initiated trials and reporting of adverse events, but observers warn that more safeguards are needed to prevent recurring ethical lapses.

via CNN|
#china-biotech#clinical-trials#ethics
Pfizer inks $10B pact with Innovent to fast-track 12 cancer drugs
business4 months ago

Pfizer inks $10B pact with Innovent to fast-track 12 cancer drugs

Pfizer and Innovent announced a broad collaboration worth up to $10 billion to develop 12 cancer medicines, starting with a $650 million upfront and up to $9.85 billion in milestones. Pfizer will gain exclusive global licenses for four programs, ex-China rights to four, and co-develop four with Innovent, while Innovent handles eight programs through phase 1. The partners will co-commercialize jointly owned assets in the U.S. and Europe, illustrating how Western pharma is leveraging China’s rapid early development to boost productivity and global reach.

via Fierce Biotech|
#business#cancer-drugs#china-biotech
China Advances Animal Testing to Lead Global Biotech Competition
science-and-technology11 months ago

China Advances Animal Testing to Lead Global Biotech Competition

Chinese scientists are pushing the boundaries of animal testing, especially with large animals like pigs and primates, to develop treatments for diseases like ALS, amid a regulatory environment that is more permissive than in the US and Europe, raising ethical concerns and strategic implications for global biotech dominance.

via Bloomberg.com|
#animal-testing#china-biotech#ethical-debate